

Warren Hanon Capell

13199 E. Montview Blvd., Suite 200 • Aurora, CO 80045 • (303) 506-8467 • warren.capell@cpcmed.org

Education

B.A., Pomona College, Claremont, CA; Aug 1988 – Jun 1992

- Walter Bertsch Prize in Biology
- Michael H. Rosen Memorial Premedical Award
- Cum Laude
- Phi Beta Kappa

M.D., University of Washington School of Medicine, Seattle, WA; Aug 1992 – Jun 1996

Employment

University of Colorado, Internal Medicine Residency, Denver, CO; Jul 1996 – Jun 1999

- Specialty Board Certification, ABIM; Aug 1999

Denver Health Walk-in Clinic, Intermittent Physician, Denver, CO; Apr 1999 – Oct 2002

Fort Logan Psychiatric Hospital, On-duty Physician, Denver, CO; Aug 1999 – Oct 2004

University of Colorado, Endocrinology Fellowship, Denver, CO; Jul 2000 – Jun 2003

- Subspecialty Board Certification, ABIM; Oct 2002
- Pfizer Scholars in Endocrinology Research Award
- NIH, National Research Service Award

University of Colorado, Div. of Endocrinology, Instructor/Fellow, Denver, CO; Jul 2003 – Feb 2005

- GCRC, Pilot & Feasibility Award Recipient

University of Colorado, Div. of Endocrinology, Assistant Professor, Denver, CO; Mar 2005 – Jun 2014

University of Colorado, Div. of Endocrinology, Associate Professor, Denver, CO; Jul 2014 – present

Academic Physician

- NIH, K-08 Award; 2005
- Medical student teaching recognition, Teaching Excellence Committee; 2006
- Colorado Multiple IRB, panel member; May 2006 – Apr 2007
- Scientific Advisory & Review Committee, member; June 2017 - present

Colorado Multiple IRB, Co-Chair; Apr 2007 – Apr 2011

Responsibilities include directing full-board meetings; full-board and expedited review; pre-review communication with investigators; HIPAA privacy review; policy development; compliance board member; international research advisory committee member

Internal Medicine Residency Program, Associate Program Director; Jul 2007 – Jun 2008

Responsibilities included resident reviews, mentoring, and career development; promotion of resident research and assisting development of research curriculum; applicant screening and interviews; assisting with recruitment presentations

Colorado Multiple IRB, Interim Director; May 2011 – Oct 2011

Colorado Multiple IRB, Director; Nov 2011 – Feb 2015

Responsibilities include office and personnel management; investigator counseling and guidance; instituting COMIRB Office Hours; policy and guidance development; directing Compliance Board, Scientific Ethics Committee, and International Research Advisory Committee meetings; IRB panel compliance review;

research community engagement; assisting with AAHRPP re-accreditation

CPC Clinical Research, Clinician-Scientist; Dec 2014 - present

Responsibilities within this Academic Research Organization include clinical trial committee leadership (e.g., event adjudication), medical safety monitoring, protocol development, and medical writing.

Colorado Multiple IRB, Expedited/Exempt reviewer, panel member; Feb 2015 – Sep 2016

Responsibilities include expedited/exempt initial, continuing, and amendment reviews; full board panel reviews; protocol development mentoring

Kinetiq, clinical research consultant; Sep 2016 – present

Responsibilities include protocol design, protocol writing, and scientific/regulatory advising

Publications

1. **Capell, WH**, A Zambon, MA Austin, JD Brunzell, and JE Hokanson. 1996. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. *Art Thromb Vasc Biol* 16: 1040-6.
2. **Capell, WH**, CA DeSouza, P Poirier, ML Bell, BL Stauffer, KM Weil, TL Hernandez, and RH Eckel. 2003. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. *Art Thromb Vasc Biol* 23: 307-13.
3. Schlaepfer, IR, LK Pulawa, LDMCB Ferreira, DE James, **WH Capell**, and RH Eckel. 2003. Increased expression of the SNARE accessory protein Munc18c in lipid-mediated insulin resistance. *J Lip Res* 44: 1174-81.
4. **Capell, WH**, KP Spiegelman, and RH Eckel. 2004. Therapeutic targets in severe hypertriglyceridemia. *Drug Disc Today Dis Mech* 1: 171-7.
5. **Capell, WH** and RH Eckel. 2005. Severe hypertriglyceridemia with history of treatment failure. *Nature Clin Pract Endo Metab* 1: 53-8.
6. **Capell, WH** and RH Eckel. 2006. Treatment of hypertriglyceridemia. *Curr Diab Reports* 6: 230-40.
7. Hernandez, TL, **WH Capell**, P Wolfe, LA Gerard, and RH Eckel. 2006. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. *Am J Cardiol* 98: 1656-9.
8. Linnebur, SA, **WH Capell**, JJ Saseen, P Wolfe, and RH Eckel. 2007. Plant sterols added to combination statin and colessevelam hydrochloride therapy failed to lower low-density lipoprotein cholesterol concentrations. *J Clin Lipidol* 1: 626-33.
9. Hernandez, TL, JP Sutherland, P Wolfe, M Allian-Sauer, **WH Capell**, ND Talley, HR Wyatt, G Foster, JO Hill, and RH Eckel. 2010. Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. *Am J Clin Nutr* 91: 1-8.
10. **Capell, WH**, IR Schlaepfer, P Wolfe, PA Watson, DH Bessesen, MJ Pagliassotti, and RH Eckel. 2010. Fatty acids increase glucose uptake and metabolism in C2C12 myoblasts stably transfected with human lipoprotein lipase. *Am J Physiol Endo Metab* 299: E576-83.
11. Wang, H, **W Capell**, JH Yoon, S Faubel, and RH Eckel. 2013. Obesity development in caspase-1-deficient mice. *Int J Obes* 38: 152-5.
12. Abernethy, AP, **WH. Capell**, NM Aziz, C Ritchie, M Prince-Paul, RE Bennett, and JS Kutner. 2014. Ethical Conduct of Palliative Care Research: Enhancing Communication Between Investigators and Institutional Review Boards. *J Pain Sympt Manage* 48: 1211-21.
13. Daddato, A, HL Wald, C Horney, DL Fairclough, EC Leister, M Coors, **WH Capell**, and RS Boxer. 2017. A randomized trial of heart failure disease management in skilled nursing facilities (SNF Connect): Lessons learned. *Clin Trials* 14: 308-13.

14. Hess, CN, L Norgren, GM Ansel, **WH Capell**, JP Fletcher, FGR Fowkes, A Gottsäter, K Hitos, MR Jaff, J Nordanstig, and WR Hiatt. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease with a Focus on Revascularization: A TASC Initiative. 2017. *Circ* 135: 2534-55.
15. **Capell, WH**, MP Bonaca, MR Nehler, E Chen, JM Kittelson, SS Anand, SD Berkowitz, ES Debus, F Fanelli, L Haskell, MR Patel, R Bauersachs, and WR. Hiatt. 2018. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). *Am Heart J* 199: 83-91.

Book Chapters

Lakin, A and **W Capell**. 2014. Regulatory aspects of biospecimen collection. In: McManus, LM and RN Mitchell (Eds.), *Pathobiology of Human Disease*. San Diego: Elsevier, Inc., 3023-9.

Professional Training

CITI Good Clinical Practice; Aug 2016
 CPC Good Clinical Practice; Jul 2017
 CITI Good Clinical Practice – Devices; Aug 2016
 CITI HIPS (HIPAA); Aug 2016
 CPC HIPAA; Jul 2017

National Committees

Public Responsibility in Medicine & Research (PRIM&R)

- PRIM&R Advancing Ethical Research Conference, Planning Committee; Poster/Abstract Subcommittee Co-Chair; 2017 - present
- PRIM&R Advancing Ethical Research Conference, Planning Committee; Poster/Abstract Subcommittee member; 2011 - 2016
- PRIM&R At Your Doorstep, IRB 250 lecture series Curriculum Editor; 2012

Local Teaching & Lectures

Adrenal Gland Disorders, Medical Student Pathophysiology Course; 2005 – 2009
Small Group Leader, Medical Student Endocrinology Pathophysiology Course; 2005 – 2009
Lipid Metabolism and Disorders, Endocrine Fellow Physiology lecture series; 2005 – 2012
Lab Testing in Adrenal Disorders, UCD Pathology 8001; 2009 – 2015
Stress-Dose Steroids and Adrenal Physiology, School of Dentistry Faculty Development Seminar; 2009
COMIRB: An interactive guide to smoother submissions, Endocrine Div. Research Conference; 2010
How the FDA and COMIRB Interact, CCTSI investigator quarterly lecture series; 2011 – 2015
Ethics, the IRB, and Community-Based Participatory Research, CCTSI Colorado Immersion Training in Community Engagement, Panelist; 2011
FDA Regulations: Drugs and Devices, COMIRB 5th Friday lecture; 2011
COMIRB and Research in a Regulatory Era; Endocrinology Grand Rounds; 2011
Research Ethics, MSI Molecules to Medicine lecture; 2011
Mock IRB, small group and debrief leader, MSI Molecules to Medicine workshop; 2011 – present
Overview of Human Subject Research Regulations, CCTSI investigator quarterly lecture series; 2012
COMIRB Submissions, CCTSI investigator quarterly lecture series; 2012 – 2015
IRB Responsibilities After Approval, CCTSI investigator quarterly lecture series; 2012 – 2015
Blood, Bytes, Biospecimens, and Banks; Ob/Gyn Grand Rounds; 2012
IRB Issues in Bioinnovation; UCD IDPT 7301; 2013
Issues and Best Practices in Biobanking; Pulmonary/Critical Care Research Conference; 2013
Introduction to the ethics and regulation of human subject research; On-line learning module, MSI Molecules to Medicine course; 2013

Biobanking in Pulmonary and Critical Care Medicine; Pulmonary Research Methods Conference; 2014

Ethics on the Borderland: Research vs. QI; UCH Hospital Wide Ethics Rounds; 2014

Privacy and the IRB; 5th Annual CCTSI Research Ethics Conference; 2014

Protocol Development Workshop, quarterly workshop series; 2016 – present

Protocol Writing and Development, quarterly lecture; 2018 – present

Regional and National Presentations

Pacific Northwest Lipid Club, 10th Annual Meeting, Seattle, WA, “Comparison of the chemical composition of LDL subclass phenotype A and phenotype B particles in healthy subjects.” Sep 1993

Western Clinical Research Forum, Carmel, CA, “Differences in particle lipid composition between low density lipoprotein subclass phenotypes.” Feb 1994

Clinical Research Annual Conference, Arlington, VA, “Effect of triglyceride lowering on endothelial dysfunction in patients with hypertriglyceridemia.” [Poster]; Mar 2001

American Heart Association Annual Conference, Anaheim, CA, “Triglyceride lowering with fenofibrate improves endothelial vasodilator function in patients with hypertriglyceridemia.” [Poster]; Nov 2001

Kern Lipid Conference, Aspen, CO, “Triglyceride lowering with fenofibrate improves endothelial vasodilator function in patients with hypertriglyceridemia.” [Poster]; Aug 2002

Kern Lipid Conference, Aspen, CO, “Triglyceride Fatty Acid Delivery to Muscle Cells: An in vitro Model to Assess Lipoprotein Lipase-Mediated Fatty Acid Uptake.” [Poster]; Aug 2003

NAASO Annual Sessions, Las Vegas, NV, “Intramyocellular Partitioning of Medium Free Fatty Acids Differs From that of Lipoprotein Triglyceride-Derived Fatty Acids.” *Obesity* 12(Suppl): A176. [Poster]; Nov 2004

NAASO Annual Sessions, Las Vegas, NV, “Lipoprotein Lipase-Mediated Triglyceride Hydrolysis is Associated with Increased Medium Glucose Disappearance and Deposition into Cell Triglyceride in Cultured Myocytes.” *Obesity* 12(Suppl): A176. [Poster]; Nov 2004

National Council of University Research Administrators, Western/Rocky Mountain Regional Conference, Denver, CO, “Operationalizing Clinical Research,” [Co-presenter, panelist]; Apr 2011

Biofrontiers Symposium 2014: Big Data, Genomics and Molecular Networks, Boulder, CO, “Panel Discussion: Genomic Research and Privacy” [panelist]; Jun 2014

27th Annual Rocky Mountain Interprofessional Research & Evidence-based Practice Symposium, Denver, CO, “Differentiating shades of gray: distinguishing research from evidence-based practice, quality improvement, and program evaluation” [Presenter, panelist]; Apr 2015

Public Responsibility in Medicine & Research, Advancing Ethical Research Annual Conference, Anaheim, CA, “Innovations in Respecting Persons” [Panel Moderator]; Nov 2016

Public Responsibility in Medicine & Research, Advancing Ethical Research Annual Conference, San Antonio, TX,

- “You'll Know It When You See It, or Will You?: Defining "Human Subjects Research" Under the Revised Common Rule” [Presenter, panelist]; Nov 2017
- “Let's Review a Protocol: Identifying and Applying Federal Regulations to the Review of Research That Requires Expedited or Full Board Review” [Presenter, panelist]; Nov 2017
- “Innovations in Research on Overlooked Ethical Perspectives” [Panel Moderator]; Nov 2017